Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma

BACKGROUND: Relatlimab plus nivolumab (anti–lymphocyte-activation gene 3 plus anti–programmed death 1 [anti–LAG-3+anti–PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is unknown. METHODS: We evaluated blood samples f...

Descripción completa

Detalles Bibliográficos
Autores principales: Huuhtanen, Jani, Kasanen, Henna, Peltola, Katriina, Lönnberg, Tapio, Glumoff, Virpi, Brück, Oscar, Dufva, Olli, Peltonen, Karita, Vikkula, Johanna, Jokinen, Emmi, Ilander, Mette, Lee, Moon Hee, Mäkelä, Siru, Nyakas, Marta, Li, Bin, Hernberg, Micaela, Bono, Petri, Lähdesmäki, Harri, Kreutzman, Anna, Mustjoki, Satu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014104/
https://www.ncbi.nlm.nih.gov/pubmed/36719749
http://dx.doi.org/10.1172/JCI164809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014104/
https://www.ncbi.nlm.nih.gov/pubmed/36719749
http://dx.doi.org/10.1172/JCI164809

Ejemplares similares